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Changing Incidence and Risk Factors for Kaposi Sarcoma
by Time Since Starting Antiretroviral Therapy:
Collaborative Analysis of 21 European Cohort Studies
Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoorda
Background. Kaposi sarcoma (KS) remains a frequent cancer in human immunodeficiency virus (HIV)–positive patients start-
ing combination antiretroviral therapy (cART). We examined incidence rates and risk factors for developing KS in different periods
after starting cART in patients from European observational HIV cohorts.
Methods. We includedHIV-positive adults starting cARTafter 1 January 1996.We analyzed incidence rates and risk factors for devel-
oping KS up to 90 and 180 days and 1, 2, 5, and 8 years after cART start and fitted univariable andmultivariable Cox regressionmodels.
Results. We included 109 461 patients from 21 prospective clinical cohorts in Europe with 916 incident KS cases. The incidence
rate per 100 000 person-years was highest 6 months after starting cART, at 953 (95% confidence interval, 866–1048), declining to 82
(68–100) after 5–8 years. In multivariable analyses adjusted for exposure group, origin, age, type of first-line regimen, and calendar
year, low current CD4 cell counts increased the risk of developing KS throughout all observation periods after cART initiation. Lack
of viral control was not associated with the hazard of developing KS in the first year after cART initiation, but was over time since
starting cART increasingly positively associated (P < .001 for interaction).
Conclusion. In patients initiating cART, both incidence and risk factors for KS change with time since starting cART. Whereas
soon after starting cART low CD4 cell count is the dominant risk factor, detectable HIV-1 RNA viral load becomes an increasingly
important risk factor in patients who started cART several years earlier, independently of immunodeficiency.
Keywords. Kaposi sarcoma; HIV; adults; antiretroviral therapy; risk factors.
Kaposi sarcoma (KS) remains a frequent cancer in human im-
munodeficiency virus (HIV)–positive patients, including in pa-
tients who are receiving combination antiretroviral therapy
(cART) [1–4]. Higher detection rates of KS and KS becoming
evident in the context of the immune reconstitution inflamma-
tory syndrome (IRIS) may contribute to the increased KS risk
shortly after cART initiation [5]. Few studies have examined
the incidence rate of KS in HIV-positive patients who started
cART some years earlier. An earlier analysis of a large US co-
hort of HIV-positive patients found that the incidence of KS
was very high in the first 6 months after cART initiation
(1342/100 000 person-years [py]) but decreased substantially
thereafter and stabilized at a rate of about 164/100 000 py >6
months after starting cART [3].
Infection with human herpesvirus 8 (HHV-8) is a necessary
cause of KS [6].HHV-8 seroprevalence is high among men who
have sex with men (MSM) and in the general population of
some regions of sub-Saharan Africa, including Southern Africa
and East Africa [6]. Likewise, high rates of KS incidence among
patients having started cART have been found among MSM in
Europe [2] and patients in Africa [7–9]. Immunodeficiency, as
indicated by low CD4 cell counts, and failure to suppress HIV
replication have also been identified as risk factors for develop-
ing KS in HIV-positive individuals receiving cART [2, 5, 10–12].
However, it is unclear at present whether these risk factors in-
fluence KS development similarly soon and many years after
starting cART. In particular, the determinants of KS among pa-
tients who started cART several years earlier have not been well
defined.
The aim of the present study was to gain a better understand-
ing of the factors that drive the incidence of KS among patients
initiating cART. We analyzed data from a large collaboration of
European HIV cohort studies, the Collaboration of Observa-
tional HIV Epidemiological Research Europe (COHERE) in
EuroCoord to examine KS incidence rates and risk factors for
KS in different time intervals after cART initiation, from 30–
90 days to 5–8 years.
MATERIALS AND METHODS
COHERE in EuroCoord
The COHERE in EuroCoord is a collaboration of 40 cohorts
of HIV-infected patients across Europe, led by 2 data centers in
Bordeaux, France, and Copenhagen, Denmark [13]. Twenty-nine
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cohorts provided data for the current project. Patients are fol-
lowed up every 3–6 months. Participating cohorts collect and
transfer standardized data using the HIV Cohorts Data Exchange
Protocol [14]. Data collected include sociodemographic factors,
CD4 cell counts, HIV-1 RNAviral load measurements, antiretro-
viral drugs, AIDS-defining events, and deaths. The data set for
this analysis was merged on 4 June 2014 and included 29 cohorts
with 306 482 patients. Cohorts adhere to local ethical require-
ments for observational research [13].
Inclusion Criteria and Definitions
We included HIV-positive adults aged ≥16 years who enrolled
and started cART after 1 January 1996, when cART became
widely available in most parts of Europe. cART was defined
as a regimen of ≥3 drugs from any class, including nucleoside
reverse-transcriptase inhibitors, nonnucleoside reverse-
transcriptase inhibitors (NNRTIs), and protease inhibitors
(PIs). We excluded patients with previous antiretroviral therapy
exposure to monotherapy or dual therapy. Patients with ≤30
days of follow-up and prevalent KS cases diagnosed before or
during the first 30 days after cART start were excluded from
analyses. We also excluded patients with missing information
for sex, country or region of birth, and date of birth and cohorts
with <100 eligible patients.
We defined baseline CD4 cell count as the measurement clos-
est to the start of cART, with a time window of −90 to +30 days.
Baseline HIV-1 RNA viral load was the measurement closest to
start cART with a time window of −90 to +7 days. Suppression
of HIV-1 replication was defined as an HIV-1 RNA viral load
≤500 copies/mL. Late presenters were defined as CD4 cell
count <350/μL or Centers for Disease Control and Prevention
stage C at enrollment [15]. First-line regimens were classified as
NNRTI based, boosted PI based, unboosted PI based, or other.
Sex and exposure groups were defined as MSM, heterosexual
men, and heterosexual women. Origin (ie, country or region
of birth) was categorized as European, African or other.
Statistical Analysis
Observation started 30 days after initiating cART. We used an
intention-to-continue-treatment approach, ignoring subse-
quent treatment changes and interruptions. We split observa-
tion time into 6 periods: 30–90 and 91–180 days, 181 days to
12 months, and 1–2, 2–5, and 5–8 years. The same patient
could contribute time to several periods. Observation ended
at the earliest of KS diagnosis, last follow-up visit, death, or
8 years after cART start. We calculated KS incidence rates by
dividing the number of patients developing KS by the number
of person-year at risk and Poisson 95% confidence intervals
(CIs). We fitted Cox models separately for each of the 6 periods,
including in the models exposure group, origin, first-line regi-
men, calendar year of enrollment (4 categories), and the time-
updated (current) variable CD4 cell count (6 categories), HIV-1
RNA viral load (4 categories), and age (4 categories). We used
the likelihood ratio test to test whether hazard ratios (HRs)
changed across time periods (test for interaction between period
and risk factor).
In additional analyses we included baseline CD4 cell count or
late presentation in the model, included square-root trans-
formed CD4 cell counts and log-transformed HIV-1 RNA
viral loads as continuous variables, and excluded the first
6 months after starting cART or patients enrolled into cohort
before 2000. All analyses were done with Stata software, version
13 (StataCorp). Results are presented as medians with inter-
quartile ranges (IQRs), incidence rates per 100 000 py, and
crude and adjusted HRs, with 95% CIs.
RESULTS
Study Population
A total of 109 461 patients from 21 cohorts from 10 European
countries (Austria, Belgium, Denmark, Germany, France, Italy,
Spain, Greece, the Netherlands, and Switzerland) or the Euro-
SIDA study [16] were eligible for the current analyses. Supple-
mentary Figure 1 shows the number of included and excluded
patients. The main reasons for excluding patients were enroll-
ment before 1996 (n = 52 717; 27%), patients who were not
starting cART (n = 63 708; 32%), and patients who were not an-
tiretroviral therapy naive at cART initiation (n = 34 644; 18%).
A total of 9347 KS cases were excluded, of which 3872 (41%)
were diagnosed before 1996. Of the post-1996 cases, 3414
(62%) were diagnosed within ≤30 days after cART initiation.
Included and excluded patients were similar with respect to
sex, age, and CD4 cell counts at enrollment (data on file). In-
cluded patients had higher HIV-1 RNA viral loads at enroll-
ment than excluded patients (median, 75 000 vs 19 407
copies/mL in included vs excluded patients). Patients who en-
rolled before 2000 were more likely than those who enrolled
later to have missing HIV-1 RNA measurements and thus to
be excluded from the multivariable analysis.
The baseline characteristics of the 109 461 included patients
are shown in Table 1: 40 972 (37%) were MSM, and 29 845
(27%) were women. The majority of patients (n = 84 514;
77%) were of European origin; 16 330 (15%) were of African or-
igin. The median (IQR) age was 37.3 (31.2–44.7) years. The me-
dian (IQR) CD4 cell count was 250/µL (122–370/µL); 15 652
patients (14%) were in Centers for Disease Control and Preven-
tion stage C. The median (IQR) follow-up since starting cART
was 4.6 (2.0–8.0) years, and the total observation time was
501 700 py.
A total of 916 patients developed KS after starting cART. The
median (IQR) time from starting cART to KS diagnosis was 223
(77–987) days. Patients with KS were more likely to be male,
MSM, and enrolled during the early years of the cART era
(1996–2000) than those remaining free of KS (Table 1).
Among 318 heterosexual patients developing KS, 66% (211)
were men and 34% (107) were women; 38% (124) were of
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African origin. Patients developing KS were often late present-
ers and started cART in a more advanced clinical stage than
those not developing KS. In the 916 patients with KS, the
CD4 cell count at KS diagnosis was <350/µL in 705 patients,
350–499/µL in 106, and ≥500/µL in 105. Patients with CD4
cell counts ≥350/µL at KS diagnosis were more likely to be
MSM, to be older, and to have higher CD4 cell counts at enroll-
ment than those with counts <350/µL at KS diagnosis. The me-
dian (IQR) viral load at KS diagnosis was 358 (0–27 750)
copies/mL, and the median (IQR) CD4 cell count was 243/µL
(107–409/µL) and 450/µL (280–596/µL) in those developing
KS 30–90 days or 5–8 years, respectively, after starting cART.
Four hundred eighteen (46%) of the KS cases were diagnosed
during the first 6 months after starting cART; these patients
had low baseline CD4 cell counts (median, 85/µL; IQR, 27–
230/µL) and were often late presenters (n = 340; 81%).
Incidence Rates
The overall KS incidence rate was 183/100 000 py (95% CI, 171–
195). It was 1472/100 000 py 30–90 days after cART initiation,
declined to 582/100 000 at 91–180 days, 247/100 000 at 181 days
to 1 year, and 120/100 000 at 1–2 years (Figure 1A). The rate was
similar in the subsequent 2 periods: about 82–85/100 000 py at
>2 years of cART initiation. Figure 1B–1F shows the incidence
rate stratified by current CD4 cell count and HIV-1 RNA viral
load, origin, exposure group, and current age. For incidence
rates per risk group and time period, see Supplementary Table 1.
In all periods after cART initiation, incidence rates were highest
in patients with current CD4 cell counts <50/µL, in those
with nonsuppressed HIV-1 RNA viral replication, and in
MSM. More than 2 years after cART initiation, the KS incidence
in MSM was about 149–160/100 000 py. The lowest rates
were observed 5–8 years after cART initiation in women (23/
100 000 py), in patients with suppressed viral load (41/
100 000 py), and in patients with CD4 cell counts ≥500/µL
(36/100 000 py).
Risk Factors by Period
A total of 100 022 patients (91.4%) had complete data and were
included in the multivariable analyses. The HRs from the mul-
tivariable Cox models by period after cART initiation are shown
in Table 2 and Supplementary Figure 2; results from univariable
analyses are shown in Supplementary Tables 2 and 3. The risk
of KS was increased in MSM, in patients of African origin, and
in those with low current CD4 cell counts. The association was
strongest for MSM (HR, 5.87 for MSM vs heterosexual men at
30–90 days after cART initiation) and for current CD4 cell
count (HR, 7.37 for <50/µL vs 350–499/µL at 30–90 days).
There was little evidence for a difference in HRs across the 6 pe-
riods for exposure group, origin, calendar year of enrollment,
first-line cART regimen or current CD4 cell count, with P val-
ues of .12–.93 from tests of interaction (Table 2). The situation
was different for current HIV-1 RNA viral load: there was no






(n = 108 545)
Exposure group
MSM 554 (60.5) 40 418 (37.2)
Heterosexual contact 211 (23.0) 32 142 (29.6)
Women 107 (11.7) 29 738 (27.4)
Unknown 44 (4.8) 6247 (5.8)
Origin
Europe 713 (77.8) 83 801 (77.2)
Africa 146 (15.9) 16 184 (14.9)
North America 49 (5.3) 6284 (5.8)
Other 8 (0.9) 2276 (2.1)
Age, median (IQR), y 38 (32.1–46.4) 37.3 (31.2–44.7)
Age group
16–30 y 152 (16.6) 22 256 (20.5)
31–40 y 366 (40.0) 43 238 (39.8)
41–50 y 233 (25.4) 27 903 (25.7)
>50 y 165 (18.0) 15 148 (14.0)
CD4 cell count, median
(IQR), cells/µL
146 (43–302) 250 (124–370)
CD4 cell count
<50/µL 224 (24.5) 12 278 (11.3)
50–99/µL 105 (11.5) 8104 (7.5)
100–199/µL 155 (16.9) 17 120 (15.8)
200–349/µL 188 (20.5) 31 793 (29.3)
350–499/µL 87 (9.5) 16 592 (15.3)
≥500/µL 62 (6.8) 10 952 (10.1)
Data missing 95 (10.4) 11 706 (10.8)
HIV RNA viral load, median
(IQR), copies/mL
147 819 (50 000–384000) 75 000 (19 000–222 000)
HIV RNA viral load
≥100 000 copies/mL 460 (50.2) 38 329 (35.3)
10 001–99 999 copies/mL 236 (25.8) 34 561 (31.8)
501–9999 copies/mL 48 (5.2) 12 322 (11.4)
≤500 copies/mL 3 (0.3) 1561 (1.4)
Data missing 169 (18.4) 21 772 (20.1)
CDC stage
A/B 640 (69.9) 90 642 (83.5)
C 237 (25.9) 15 415 (14.2)
Data missing 39 (4.3) 2488 (2.3)
Late presentation
No 231 (25.2) 42 096 (38.8)
Yes 649 (70.9) 60 753 (56.0)
Data missing 36 (3.9) 5696 (5.2)
First-line cART regimen
Nonboosted PI 253 (27.6) 21 478 (19.8)
Boosted PI 334 (36.5) 37 918 (34.9)
NNRTI without PI 293 (32.0) 42 581 (39.2)
Other 36 (3.9) 6568 (6.1)
Calendar year of enrollment
1996–2000 336 (36.7) 29 676 (27.3)
2001–2005 334 (36.5) 35 781 (33.0)
2006–2010 191 (20.9) 32 844 (30.3)
2011–2014 55 (6.0) 10 244 (9.4)
Abbreviations: cART, combination antiretroviral therapy; CDC, United States Centers for
Disease Control and Prevention; HIV, human immunodeficiency virus; IQR, interquartile
range; KS, Kaposi sarcoma; MSM, men who have sex with men; NNRTI, nonnucleoside
reverse-transcriptase inhibitor; PI, protease inhibitor.
a Data represent No. (%) of patients unless otherwise specified.









alavasi user on 16 N
ovem
ber 2020
evidence of an association in the periods early after cART initi-
ation, but an increasingly strong association emerged in the
later periods (P < .001). The HR comparing viral loads
≥100 000 copies/mL with those ≤500 copies/mL was 3.08
(95% CI, 1.56–6.09) at 1–2 years after cART initiation and
9.72 (95% CI, 5.34–17.7) at 5–8 years.
In the overall multivariable analysis not stratified by time pe-
riod (Supplementary Table 4), patients aged >50 years had a
higher KS risk compared with those aged ≤30 years. There was
some evidence for an interaction between current age and time
since starting cART (P = .07). However, this finding was not ro-
bust in additional analyses (data on file). The baseline CD4 cell
count (Supplementary Table 5) and late presentation (Supple-
mentary Table 6) were associated with the risk of KS in the
early periods after cART initiation but not thereafter. Results
were similar when square-root-transformed current CD4 cell
counts and log-transformed HIV-1 RNAviral loads were includ-
ed as continuous variables rather than categories of current CD4
cell count and HIV-1 RNA viral load (data on file). Tests for in-
teraction for current CD4 cell and current HIV RNA viral load
were similar when we excluded the first 6 months after cART ini-
tiation (P = .41 and .004, respectively) and when we excluded pa-
tients enrolled before 2000 (P = .49 and <.001, respectively).
DISCUSSION
In this collaborative analysis, we found that the incidence rate of
KS was about 1500/100 000 py in the first weeks after starting
cART but declined thereafter to plateau at about 82–85/
100 000 py after 2 years. In MSM the KS incidence rate was
about 149–160/100 000 py, even 2 years after starting cART.
This is higher than the age-standardized incidence of the
most frequent cancers in the general population (breast and
prostate cancer, 80/10 000 py and 70/10 000 py, respectively
[17]). Other patient groups with high KS incidence rates were
migrants from sub-Saharan Africa, late presenters, and patients
with low CD4 cell counts. The lowest KS incidence rates were
seen in heterosexual women who had started cART several
years earlier. The strength of associations with KS in the differ-
ent periods tended to be similar for most risk factors, with the
exception of HIV-1 viral load. Viral load was not associated
with KS up to 1 year after starting cART, but it emerged as
an increasingly important risk factor thereafter.
Our analysis was based on a large European cohort collabo-
ration including >100 000 patients and >500 000 py of follow-
up with longitudinal measurements of CD4 cell count and
HIV-1 RNA viral load and detailed information on origin, sex-
ual orientation, and drug regimens. This is one of few studies in
patients who have started cART ≥5 years earlier [2, 3] and, to
the best of our knowledge, the first study to thoroughly examine
changes in the importance of different risk factors over time
since cART initiation, using time-updated values where appro-
priate. Our study has several limitations. Data on HHV-8 seros-
tatus, KS stage, or KS-related IRIS were not available. For
example, we could not assess whether the increased risk of KS
during the first 6 months after cART initiation was related to
IRIS [5]. The risk of unmasking IRIS is increased in patients
Figure 1. Kaposi sarcoma incidence rates overall and stratified for selected risk factors by time periods since start of combination antiretroviral therapy (cART).
Abbreviations: HIV, human immunodeficiency virus; MSM, men who have sex with men; py, person-years.









alavasi user on 16 N
ovem
ber 2020
with low CD4 cell count nadir at cART initiation [18], and pre-
vious studies have shown that timely initiation of cART at high
CD4 cell counts may reduce the risk of developing unmasking
IRIS-KS [18–20].
The most striking finding of our study is the emergence of
HIV-1 RNA viral load as an increasingly strong risk factor for
KS in patients who had started cART several years earlier. In
this multivariable analysis the association between current
HIV-1 RNA viral load and KS was independent of other risk
factors, including immunodeficiency, and a dose-response rela-
tion was evident, with the highest risk of KS in those with viral
loads ≥100 000 copies/mL. It therefore seems that soon after
starting cART the incidence of KS is largely driven by immuno-
deficiency, whereas later on replicating HIV-1 and immunode-
ficiency independently contribute to the risk of KS. This might
be explained by synergistic interactions between HIV and
HHV-8 [21]. The HIV-1 Tat protein facilitates HHV-8 replica-
tion, which in turn may lead to an increased risk of KS [22, 23].
Likewise, HHV-8 has been shown to activate HIV replication
[24]. Our results indicate that consistent long-term suppression
of HIV-1 RNA replication may prevent such interactions and
thus may reduce the risk of KS. These findings suggest that
Table 2. Risk Factors for Developing KS by Time Since cART Initiationa
Risk Factor
HR (95% CI) by Time Since cART Initiation
P Valueb30–90 d 91–180 d 6–12 mo 1–2 y 2–5 y 5–8 y
Patients with KS/total, No. 201/90 789 130/91 646 116/90 511 93/85 735 156/75 503 94/48 498
Exposure group
MSM 5.87 (3.90–8.83) 2.84 (1.84–4.39) 3.32 (2.05–5.37) 3.00 (1.78–5.05) 4.17 (2.73–6.35) 4.43 (2.55–7.70) .46
Heterosexual men (Ref) 1.00 1.00 1.00 1.00 1.00 1.00
Women 0.86 (.50–1.48) 0.54 (.30–.96) 0.62 (.33–1.16) 0.67 (.34–1.30) 0.65 (.37–1.13) 0.41 (.18–.95)
Origin
European (Ref) 1.00 1.00 1.00 1.00 1.00 1.00 .93
African 2.01 (1.23–3.28) 2.07 (1.23–3.47) 2.22 (1.26–3.90) 2.21 (1.19–4.12) 1.96 (1.19–3.24) 1.69 (.84–3.40)
Other 0.86 (.49–1.51) 1.53 (.84–2.80) 0.67 (.29–1.55) 1.22 (.52–2.89) 1.02 (.53–1.98) 0.65 (.23–1.83)
Age groupc
16–30 y (Ref) 1.00 1.00 1.00 1.00 1.00 1.00 .07
31–40 y 1.04 (.67–1.64) 2.01 (1.05–3.85) 1.37 (.75–2.50) 1.31 (.62–2.74) 0.92 (.54–1.59) 0.56 (.27–1.17)
41–50 y 1.34 (.85–2.13) 1.70 (.85–3.39) 1.08 (.56–2.08) 1.65 (.77–3.52) 0.83 (.47–1.48) 0.28 (.13–.62)
>50 y 1.52 (.92–2.51) 2.74 (1.35–5.58) 1.90 (.97–3.73) 2.42 (1.09–5.40) 1.21 (.66–2.22) 0.52 (.23–1.16)
CD4 cell countc
<50/µL 7.37 (4.26–12.7) 7.56 (3.85–14.8) 14.10 (6.68–29.8) 9.15 (4.06–20.6) 6.41 (3.40–12.1) 7.08 (3.32–15.1) .50
50–99/µL 4.93 (2.77–8.80) 5.53 (2.86–10.7) 4.33 (1.90–9.88) 4.24 (1.79–10.0) 4.35 (2.18–8.68) 1.90 (.62–5.86)
100–199/µL 3.46 (2.04–5.85) 2.89 (1.56–5.34) 4.16 (2.20–7.87) 1.43 (.66–3.11) 2.32 (1.31–4.11) 3.24 (1.60–6.54)
200–349/µL 1.89 (1.13–3.14) 1.52 (.83–2.77) 1.62 (.84–3.12) 1.04 (.53–2.05) 1.45 (.89–2.36) 1.33 (.68–2.59)
350–499/µL (Ref) 1.00 1.00 1.00 1.00 1.00 1.00
>500/µL 0.40 (.17–.94) 0.76 (.36–1.59) 1.05 (.53–2.07) 0.91 (.49–1.71) 0.62 (.38–1.00) 0.59 (.32–1.11)
HIV RNA viral loadc
≥100 000 copies/mL 1.46 (.96–2.20) 1.65 (.99–2.75) 1.81 (.96–3.41) 3.08 (1.56–6.09) 5.34 (3.20–8.92) 9.72 (5.34–17.7) <.001
10 001–99 999 copies/mL 1.04 (.65–1.68) 0.70 (.34–1.43) 1.51 (.77–2.96) 2.10 (1.07–4.12) 3.90 (2.46–6.19) 2.24 (1.11–4.53)
501–9999 copies/mL 1.28 (.87–1.88) 1.04 (.65–1.66) 1.46 (.83–2.55) 0.95 (.46–1.97) 2.24 (1.35–3.73) 2.25 (1.13–4.46)
≤500 copies/mL (Ref) 1.00 1.00 1.00 1.00 1.00 1.00
First-line cART regimen
Nonboosted PI 0.53 (.32–.90) 0.82 (.46–1.46) 1.65 (.88–3.08) 0.86 (.46–1.62) 0.95 (.58–1.53) 0.91 (.49–1.68) .12
Boosted PI (Ref) 1.00 1.00 1.00 1.00 1.00 1.00
NNRTI without PI 0.58 (.42–.81) 1.10 (.72–1.69) 1.05 (.66–1.65) 0.84 (.50–1.41) 0.90 (.60–1.36) 0.61 (.32–1.14)
Other 0.50 (.22–1.15) 1.41 (.70–2.86) 1.21 (.50–2.90) NA 0.35 (.13–.99) 0.52 (.18–1.54)
Calendar year of enrollment .39
1996–2000 (Ref) 1.00 1.00 1.00 1.00 1.00 1.00
2001–2005 1.20 (.77–1.89) 0.79 (.48–1.29) 1.84 (1.03–3.31) 0.60 (.34–1.08) 1.23 (.80–1.87) 0.99 (.57–1.71)
2006–2010 0.88 (.53–1.44) 0.66 (.38–1.18) 1.77 (.91–3.43) 0.70 (.37–1.33) 0.77 (.42–1.41) 0.75 (.17–3.34)
2011–2014 1.29 (.71–2.32) 1.01 (.46–2.21) 1.46 (.54–3.95) NA NA NA
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; KS, Kaposi sarcoma; MSM, men who have sex with men;
NA, not available; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; Ref, referent group.
a Results from multivariable Cox regression model, including only cases with no missing values for any of the covariates. Data represent HR (95% CI) unless otherwise specified; HRs are
stratified by cohort and adjusted for exposure group, origin, current age, current CD4 cell counts, current HIV RNA viral loads, first-line cART regimen, and calendar period of enrollment.
b P value for change over time from test of interaction.
c Time-updated data.
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monitoring viral load to detect treatment failures in a timely
fashion might be important.
The KS incidence rates from this study are generally similar
to estimates of previous studies [1–3] from Europe and the
United States (see Supplementary Table 7). Our study confirms
that MSM have a higher risk of developing KS than heterosexual
men [10, 25–27], probably owing to the higher seroprevalence of
HHV-8 infection, whereas women are at lower risk of develop-
ing KS than men [10, 27, 7]. This and other studies have shown
that Europeans have lower KS incidence rates than migrants
from sub-Saharan Africa [10, 28],which may again be explained
by the higher HHV-8 seroprevalence in patients with African
origins [6].
Previous studies have suggested that the risk of developing KS
increases with age in patients who are not receiving cART [28]
but not in patients who have started cART [2, 3, 28]. Our overall
analysis not stratified by time period suggested an increased KS
risk in patients aged >50 years compared with those aged ≤30
years. However, we did not observe a dose-response relation-
ship, and there was no robust evidence for an interaction with
time since starting cART.
In contrast to a 2015 study [29], our study did not show that
boosted PI-based first-line regimens were associated with a
lower risk of developing KS than NNRTI-based regimens. We
cannot exclude the possibility that confounding by indication
may have influenced our findings. Moreover, we examined the
initial first-line regimen only and adopted an intention-to-con-
tinue-treatment approach, which ignored subsequent treatment
changes and therefore limited our ability to detect associations
of KS with different cART regimens. We found that low current
CD4 cell counts increased the risk of developing KS in each pe-
riod after starting cART, whereas baseline CD4 cell count or late
presentation predicted KS in the first months after cART initi-
ation only. This finding is in line with findings of a previous
study [3], which showed that low baseline CD4 cell counts
were associated with an increased risk of developing KS in the
first 6 months after starting cART but not thereafter.
The risk of developing KS is particularly high in late present-
ers and patients with low current CD4 cell counts shortly after
cART initiation. This observation might be explained by an in-
creased vigilance of patients and physicians for signs of disease
but also by unmasking IRIS-associated KS [20]. KS incidence
and its associated risk factors in patients who started cART sev-
eral years earlier is not completely understood. Our study con-
firms that low current CD4 cell count increases the risk of KS
throughout all time periods after starting cART.
In conclusion, this collaborative analysis of European HIV
cohort studies shows that in patients starting cART both inci-
dence and risk factors for KS change with treatment duration.
Whereas immunodeficiency is the dominant risk factor soon
after starting cART, detectable HIV-1 RNA viral load becomes
an increasingly important risk factor in patients who started
cART several years earlier, independently of immunodeficiency.
Further research is needed on the interaction between HIV-1
and HHV-8 replication and the risk of KS, and the potential im-
pact of cART on HHV-8 viremia.
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